GlassScriptPhysician profile
Shara M Beckwith
NPI 1609864974
$12,258.40
in general payments reported to CMS, 2019-2025
39 companies · $2,713 in 2025
The $2,713 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,510 · 2022: $2,524 · 2023: $2,076 · 2024: $2,435 · 2025: $2,713.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,224.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,224.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,008.40 | 2021-2025 | |
| Novo Nordisk INC | $1,621.32 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $1,200.82 | 2021-2025 | |
| Lilly USA, LLC | $1,065.60 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $948.91 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $939.70 | 2021-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $439.09 | 2022-2025 | |
| Esperion Therapeutics, INC. | $429.13 | 2021-2025 | Nexletol |
| Amgen INC. | $425.69 | 2021-2025 | Repatha, Otezla, Otezla |
| Takeda Pharmaceuticals U.S.A., INC. | $410.49 | 2021-2025 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $354.33 | 2021-2025 | Jardiance, Synjardy, Spiriva Respimat |
| Biohaven Pharmaceuticals, INC. | $237.09 | 2021 | |
| Novartis Pharmaceuticals Corporation | $227.67 | 2021-2025 | |
| Phathom Pharmaceuticals, INC. | $215.24 | 2024-2025 | Voquezna |
| Janssen Pharmaceuticals, INC | $204.80 | 2021-2022 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $188.68 | 2025 | Korlym |
| Abbott Laboratories | $187.49 | 2021-2023 | Freestyle Libre 2 |
| Biohaven Pharmaceutical Holding Company LTD. | $134.42 | 2022 | |
| Lundbeck LLC | $127.66 | 2024-2025 | Vyepti |
| Sanofi-Aventis U.S. LLC | $117.87 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $113.72 | 2021-2025 | Vaxneuvance, Enflonsia, Capvaxive |
| Exact Sciences Corporation | $97.62 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $86.22 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $65.62 | 2024 | Gemtesa |
| Astellas Pharma US INC | $64.30 | 2021-2024 | Veozah |
| Radius Health, INC. | $52.64 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $40.23 | 2021-2022 | |
| Amarin Pharma, INC. | $39.82 | 2021-2022 | |
| Axsome Therapeutics, INC. | $30.94 | 2024-2025 | Auvelity |
| Sanofi Pasteur INC. | $26.40 | 2025 | |
| Xeris Pharmaceuticals, INC. | $22.60 | 2023 | Gvoke Hypopen |
| Daiichi Sankyo INC. | $21.36 | 2021 | |
| Nestle Healthcare Nutrition INC. | $19.35 | 2021 | |
| Baxter Healthcare | $18.14 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Inari Medical, INC. | $17.92 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Tris Pharma INC | $17.26 | 2023 | Dyanavel Xr |
| Currax Pharmaceuticals LLC | $14.14 | 2023 | Contrave, Nexlizet, Nexletol |
| Kowa Pharmaceuticals America, INC. | $13.52 | 2025 | Zoryve |
| Amneal Pharmaceuticals LLC | $12.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shara Beckwith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.